Related Experiment Video

Updated: Mar 2, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K

Midostaurin Gets FDA Nod for AML

    Cancer Discovery
    |May 21, 2017
    PubMed

    Insights

    The FDA approved midostaurin plus chemotherapy for acute myeloid leukemia (AML). This targeted therapy is the first for FLT3-mutated AML, a high-risk subtype.

    Area of Science:

    • Oncology
    • Pharmacology
    • Molecular Biology

    Background:

    • Acute myeloid leukemia (AML) is a heterogeneous blood cancer.
    • FLT3 mutations are present in approximately 25% of AML cases.
    • FLT3 mutations are associated with poor prognosis and outcomes in AML patients.

    Purpose of the Study:

    • To evaluate the efficacy and safety of midostaurin in combination with chemotherapy for AML.
    • To assess midostaurin as a targeted therapy for FLT3-mutated AML.

    Main Methods:

    • Clinical trial evaluating midostaurin plus standard chemotherapy.
    • Focus on patients with FLT3-mutated AML.
    • Analysis of treatment response and survival outcomes.

    Main Results:

    • FDA approval granted for midostaurin in combination with chemotherapy.
    • Midostaurin is the first drug approved to specifically target FLT3 mutations in AML.
    • Addresses a critical unmet need in a subset of AML patients.

    Conclusions:

    • Midostaurin offers a new targeted treatment option for FLT3-mutated AML.
    • Represents a significant advancement in personalized medicine for AML.
    • Improved outcomes are anticipated for patients with this specific mutation.

    More Related Videos

    Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

    Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

    Published on: January 5, 2024

    2.0K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.9K

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    294
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K
    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

    Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
    Phenothiazines, such as prochlorperazine...
    987
    Drugs that Stabilize Microtubules01:15

    Drugs that Stabilize Microtubules

    Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
    2.8K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.9K
    Drug Administration and Therapy Phases: Overview01:26

    Drug Administration and Therapy Phases: Overview

    Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
    The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
    The pharmacokinetic phase...
    1.6K